What is AEON stock price today?

AEON (Aeon Biopharma Inc) stock is trading at $1.20 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is AEON stock going up or down today?

AEON stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy AEON stock now?

The decision to buy AEON depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is AEON a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for AEON based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is AEON stock overvalued or undervalued?

Use our DCF valuation calculator to determine if AEON is overvalued or undervalued based on fundamental analysis and future cash flow projections.

What is AEON's P/E ratio?

P/E ratio data for AEON will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.

What is AEON's market cap?

AEON (Aeon Biopharma Inc) has a market capitalization of $0.01 billion, making it a small-cap stock.

What is AEON's price to book ratio?

Price-to-book ratio for AEON is available on our dashboard along with other valuation metrics.

Does AEON pay dividends?

AEON does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is AEON's dividend yield?

AEON does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is AEON stock a good long-term investment?

AEON's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is AEON's revenue growth rate?

Revenue growth data for AEON is available on our dashboard with detailed financial statement analysis.

Profitability metrics for AEON are available on our dashboard with complete income statement analysis.

What are the risks of investing in AEON?

Key risks for AEON include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does AEON compare to its competitors?

Compare AEON to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize AEON's performance and positioning.

What is AEON's stock price target for 2026?

Our AI model provides price targets for AEON based on fundamental analysis: Bull case $1.56 (+30%), Base case $1.38 (+15%), Bear case $1.08 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about AEON?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for AEON. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is AEON's next earnings report?

AEON reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

AEON - Aeon Biopharma Inc

NYSE * Health Care * Biotechnology

$1.20

+$0.06 (+5.26%)

About Aeon Biopharma Inc

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceutical Co., LTD., and Viatris Inc. The company is based in Irvine, California.

AEON Key Statistics

Market Cap

$10.95M

EPS

$-13.91

Employees

How AEON Compares to Peers

AEON is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

N/A

of 5

Growth Rank

N/A

of 5

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
AEON(This stock)	$10.95M	N/A	0%	0.0%	-
AMGNAmgen Inc	$178.24B	25.6	0%	0.2%	vs AMGN
GILDGilead Sciences	$154.99B	19.3	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$113.35B	31.2	0%	0.3%	vs VRTX
REGNRegeneron Pharmaceuticals	$77.69B	17.6	0%	0.3%	vs REGN
BIIBBiogen Inc	$24.26B	15.1	0%	0.2%	vs BIIB

Aeon Biopharma Inc Company Information

Headquarters: California; U.S.A
Website: www.aeonbiopharma.com
Sector: Health Care
Industry: Biotechnology

Data Updated: January 21, 2026 at 3:05 AM EST

Ready to invest in AEON?

Commission-free trading available. Affiliate links.

AEON Lician Score

5% confidence

4.0/10

Neutral

AEON has a Lician Score of 4/10 (Average). Areas of concern: Growth.

value

5.0

growth

2.0

quality

5.0

momentum

5.0

safety

5.0

The Lician Score is a comprehensive 1-10 rating that evaluates AEONacross five key dimensions: Value (valuation relative to sector),Growth (revenue and earnings trajectory),Quality (profitability and balance sheet strength),Momentum (price trends and analyst sentiment), andSafety (volatility and risk metrics).

AEON Financial Snowflake

5-axis analysis across key investment dimensions

4.4/10

Neutral

5.0

Value

Valuation vs. sector peers

2.0

Growth

Revenue & earnings trajectory

5.0

Quality

Profitability & moat strength

5.0

Momentum

Price trends & analyst sentiment

5.0

Safety

Financial stability & risk

Upcoming Events for AEON

Dashboard

Enter a ticker to analyze